AN2 Therapeutics, Inc. ANTX
Set alert
4.23 USD -0.12 -2.76%
As of Nov 3, 11:41 AM ET
4.18 Day range 4.55
1.00 52-week range 7.19
- YTD
- +271.05%
- 1 year
- +267.83%
- Open
- 4.38
- Prev close
- 4.35
- Mkt cap
- 159.62M
- Vol
- 36.27K
- Avg vol
- 265.01K
- EPS
- -1.05
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.18
- High
- 4.55
- Forward P/E
- -1.17
- Beta
- -0.22
- Short ratio
- 0.82
- Inst. own
- 52.31%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 1.22
- 200-d avg
- 1.88
- 1y target
- 2.67
6M chart
Signals (27)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 27, 2026 | 1 week ago |
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| RSI: Oversold | Oct 13, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 4 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 4 weeks ago |
| SMA: Bullish | Oct 1, 2026 | 1 month ago |
| MACD: Buy Signal | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 19, 2026 | 2 months ago |
| RSI: Overbought | Aug 12, 2026 | 2 months ago |
| RSI: Overbought | Aug 4, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 21, 2026 | 3 months ago |
| SMA: Bullish | Jul 14, 2026 | 3 months ago |
| SMA: Bearish | Jul 10, 2026 | 3 months ago |
| SMA: Bullish | Jul 9, 2026 | 3 months ago |
Newest 20 of 27.
Analyst view
Price target (mean) 2.67 -37.0% downside
Now 4.23
- Target (low)
- 1.00
- Target (mean)
- 2.67
- Target (high)
- 5.00
Ratings (0m) 5 1 buy · 3 hold · 1 sell
- Strong buy1
- Buy0
- Hold3
- Sell1
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.26 | -0.34 – -0.20 | -0.57 | +54.4% | 0 | 0.0% | 3 |
| Next quarter | -0.235 | -0.25 – -0.22 | -0.56 | +58.0% | 0 | 0.0% | 2 |
| Current year | -1.45 | -1.45 – -1.45 | -2.74 | +47.1% | 0 | 0.0% | 1 |
| Next year | -1.16 | -1.44 – -1.00 | -1.45 | +19.8% | 0 | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Nov 18, 2024 | TD Cowen | Downgrade | Buy | Hold |
| Aug 9, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Jul 3, 2024 | Leerink Partners | Upgrade | Market Perform | Outperform |
| May 16, 2024 | Evercore ISI Group | Maintained | In-Line | In-Line |
| Apr 2, 2024 | JMP Securities | Upgrade | Market Perform | Market Outperform |
| Apr 1, 2024 | Oppenheimer | Reiterated | Perform | Perform |
| Feb 13, 2024 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Feb 12, 2024 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Feb 12, 2024 | Oppenheimer | Downgrade | Outperform | Perform |
| Feb 12, 2024 | JMP Securities | Downgrade | Market Outperform | Market Perform |
| Jan 4, 2024 | JMP Securities | Initiated | — | Market Outperform |
| Mar 30, 2023 | Oppenheimer | Maintained | — | Outperform |
| Nov 14, 2022 | SVB Leerink | Maintained | — | Outperform |
| Apr 19, 2022 | Evercore ISI Group | Initiated | — | Outperform |
| Apr 19, 2022 | Oppenheimer | Initiated | — | Outperform |
| Apr 19, 2022 | Cowen & Co. | Initiated | — | Outperform |